Hylomorph develops innovative medical devices and drug-device combinations focused on preventive medicine. Their technology targets implantable medical devices to prevent post-surgery complications and improve patient well-being. The company aims to empower clinicians with advanced solutions that enhance patient outcomes following medical procedures.
Funding
$5.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Implantable medical devices are often susceptible to fibrotic encapsulation, leading to inflammation, device malfunction, and compromised patient outcomes. Current solutions do not adequately prevent the body's natural foreign-body response, resulting in complications and the need for revision surgeries.
Solution
Hylomorph develops advanced materials and device designs that minimize fibrotic encapsulation of implantable medical devices, improving device integration and long-term performance. Their technology aims to prevent complications such as inflammation and device failure by modulating the body's response to foreign materials. By creating a more biocompatible interface, Hylomorph's solutions enhance patient well-being and reduce the need for additional medical interventions. The company focuses on improving the standard of care for patients receiving implantable devices, empowering doctors to deliver better outcomes.
Target Audience
Hylomorph's primary customers are medical device manufacturers and healthcare providers focused on improving patient outcomes with implantable devices.
Features
- Proprietary materials engineered to minimize the foreign body response
- Device designs that promote tissue integration and reduce encapsulation
- Solutions applicable to a range of implantable medical devices, including CIEDs (Cardiac Implantable Electronic Devices)
- Enhanced biocompatibility to improve long-term device performance